Join the Atazanavir group to help and get support from people like you.
Atazanavir News
FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults
PRINCETON, N.J. – January 29, 2015 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Evotaz (atazanavir 300 mg...
FDA Medwatch Alert: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions
[UPDATED 04/26/2012] FDA notified healthcare professionals that the Victrelis drug label has been revised to state that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease...
FDA Medwatch Alert: Statins and HIV or Hepatitis C Drugs: Drug Safety Communication - Interaction Increases Risk of Muscle Injury
ISSUE: FDA notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins ...
FDA Medwatch Alert: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication - Drug Interactions
[Posted 02/09/2012] ISSUE: FDA notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir) and certain...
Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period
ROCKVILLE, Md., Feb. 4, 2011--On February 4, 2011, FDA approved new labeling for Reyataz (atazanavir) to include dosing recommendations for treatment of HIV-1 infection during pregnancy and...